Launching a new product in a packed pharmaceutical market requires an incisive marketing strategy. Learn more here: ...

Healthcare is moving its focus from the quantity of real-world data (RWD) to quality, with targeted AI a key tool. We explore ...

Multiple big pharma companies are reported to be circling Revolution, a cancer biotech with a market cap of $23bn.

AbbVie's deal with RemeGen is the first to be announced during the 2026 J.P Morgan Healthcare Conference, with more deals ...

A new co-innovation lab in the San Francisco Bay area will see Lilly and NVIDIA scientists work alongside each other to fuel ...

MediLink Therapeutics has signed an exclusive licensing agreement with Roche for the development and commercialisation of ...

Clinical and commercial quality controls are eased as the FDA looks to expedite therapy approvals in areas of unmet need.

Novartis has announced plans to construct a new US radioligand therapy (RLT) manufacturing facility in Winter Park, Florida.

After signing a drug pricing deal with the White House, J&J will now offer some of its branded medicines at discounted rates ...

The deal marks Lilly’s first in the M&A arena in 2026 as the company diversifies its pipeline beyond obesity drugs.

Alveus Therapeutics has debuted with $160m in Series A financing, as the biotech looks to join the crowded obesity sector ...

According to the registration form, Aktis intends to use a large portion of the IPO proceeds on the two programmes. Around ...